|
Sub-category:
Other: patient care
Category:
Patient Care
Meeting:
2008 ASCO Annual Meeting
Abstract No:
9583
Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 9583)
Author(s):
K. D. Crew, E. Shane, S. Cremers, D. J. McMahon, D. Irani, A. Sierra, D. L. Hershman
Abstract:
Background: Vitamin D deficiency (VitDdef) is common in the general population and has been associated with breast cancer (BC) risk. Low dietary intake, lack of sunlight exposure, and factors such as age, race, and obesity contribute to VitDdef. The purpose of this study is to determine the prevalence of VitDdef, as measured by serum 25-hydroxyvitamin D (25OHD), in premenopausal women at initial diagnosis of BC and after one year of vitamin D supplementation. Methods: The study included 103 premenopausal women from the northeastern US with invasive BC, median age 43 (27-54); median BMI 25 mg/kg2 (18-44); White/Hispanic/Black/Asian: 53/35/12/3. All received adjuvant chemotherapy and participated in a one-year bisphosphonate (BP) intervention trial during which they also received cholecalciferol (vitamin D3) 400 IU daily (the recommended dietary allowance or RDA). At baseline, 6 and 12 months, bone mineral density (BMD) measurements were obtained at the lumbar spine, femoral neck and total hip and blood was collected and analyzed in batches for serum 25OHD (Diasorin RIA) and other hormones (PTH, LH, FSH, estradiol). Vitamin D insufficiency was defined as 25OHD 20-30 ng/ml, deficiency 12-19 ng/ml, and severe deficiency<12 ng/ml. Information was collected on demographic, clinical and tumor characteristics. Results: At baseline, over 84% of women VitDdef (median 25OHD=15.2 ng/ml); VitDdef was less common in white women (White/Hispanic/Black: 78%/91%/90%). After vitamin D supplementation for one year, <10% of Whites and Hispanics and no Blacks achieved sufficient serum 25OHD levels (>30 ng/ml). Vitamin D levels did not correlate with baseline, 6 month or 12 month BMD, nor were they related to change in BMD from baseline in the placebo group. Chemotherapy did not significantly alter serum 25OHD. Levels of vitamin D will be correlated with serum hormone metabolites. Conclusions: VitDdef is highly prevalent in women with BC, particularly among blacks and Hispanics. The current RDA of vitamin D is too low to raise serum 25OHD above 30 ng/ml. VitDdef can increase the risk of hypocalcemia during bisphosphonate treatment. As vitamin D is essential for bone health and may be associated with BC risk, serum 25OHD levels should be measured and adequately supplemented in women with BC.
Abstract Disclosures
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy
and are designated with a caret symbol (^) here and in the print version.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by K. D. Crew :
Presentations by K. D. Crew :
Educational Book Manuscripts by K. D. Crew :
|
